Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) EPS (Weighted Average and Diluted) (2024 - 2025)

Evommune (EVMN) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with $15.14 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 203.7% to $15.14 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$11.22 for FY2025, 75.23% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $15.14 at Evommune, up from -$8.07 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $15.14 in Q4 2025, with the low at -$14.6 in Q4 2024.